AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update
MWN-AI** Summary
AIM ImmunoTech Inc. (NYSE American: AIM) reported its second-quarter financial results for 2025, highlighting significant progress in its clinical pipeline, particularly regarding Ampligen® (rintatolimod) and its collaboration with AstraZeneca for treating pancreatic cancer. CEO Thomas K. Equels emphasized the company’s commitment to addressing the challenges of pancreatic cancer, an aggressive disease, and expressed optimism about recent clinical data showing promising outcomes in overall survival (OS) and progression-free survival (PFS) without significant toxicity for patients.
In the second quarter, AIM resumed trading on the NYSE American and successfully closed a public equity offering in July, raising $8 million in gross proceeds, which is expected to sustain operations for about 12 months. The company remains focused on a Phase 2 trial evaluating Ampligen in combination with AstraZeneca's Imfinzi® (durvalumab) for patients with stable metastatic pancreatic cancer following FOLFIRINOX treatment. A mid-year update from this study indicated positive results, further enhancing AIM’s clinical profile.
Financially, as of June 30, 2025, AIM reported cash and investments amounting to $835,000. Research and development expenses rose slightly to $1.2 million compared to the previous year, while general and administrative expenses decreased to $1.5 million. The net loss from operations for the quarter increased to $2.8 million, or $(3.68) per share, versus $1.8 million, or $(3.00) per share, in Q2 2024.
AIM continues to advance its innovative therapeutics aimed at cancer and immune disorders, with Ampligen as its lead investigational drug. The company plans to present further findings at several upcoming scientific congresses, underscoring its dedication to making strides in immunotherapy.
MWN-AI** Analysis
AIM ImmunoTech (NYSE American: AIM) has delivered a significant update in its second-quarter 2025 report, particularly highlighting its pipeline program with Ampligen (rintatolimod) in collaboration with AstraZeneca for pancreatic cancer treatment. The promising data regarding the combination therapy has positioned AIM strategically within the biotech landscape, especially considering the critical need for effective treatments against aggressive malignancies like pancreatic cancer.
One of the most notable developments is the positive mid-year report from the Phase 2 DURIPANC clinical study, which indicates encouraging signs of both safety and efficacy—in this case, a lack of significant toxicity and improved progression-free survival (PFS) and overall survival (OS) for patients. This positions AIM favorably against competitors in a challenging field, potentially enhancing its appeal to investors.
Financially, AIM has improved its liquidity through an $8 million public equity offering, which will fund operations for approximately 12 months. However, it's important to note that the company reported a net loss of $2.8 million for Q2 2025. While this is an increase from the previous year, the significant investment in R&D suggests a commitment to advancing its pipeline.
Investors should be cautiously optimistic. The encouraging clinical data, coupled with a stable cash position, suggests AIM has the potential for growth, especially if it continues to yield positive results in ongoing studies. However, potential investors should remain vigilant about the inherent risks in clinical trials and the biotechnology sector at large, as the path to regulatory approval can be fraught with challenges.
In summary, while AIM ImmunoTech shows promise, a careful analysis of risk versus reward is essential when considering investment, particularly given the volatility often seen with biotech stocks.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Continued progress across pipeline programs with focus on pancreatic cancer
Mid-year report of Ampligen ® (rintatolimod) in combination with AstraZeneca’s Imfinzi ® (durvalumab) for the treatment of pancreatic cancer demonstrates promising signs of both no significant toxicity and superior PFS and OS
Bolstered cash position provides runway to fund operations for approximately 12 months
OCALA, Fla., Aug. 15, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported its financial results for the second quarter 2025.
“Through the second quarter, we continued to prioritize and accelerate our development efforts for Ampligen, particularly in our Phase 2 trial for locally advanced pancreatic cancer in collaboration with Erasmus Medical Center and AstraZeneca. We remain encouraged by the growing body of positive clinical data demonstrated to date and believe that as we build momentum, we are well positioned to execute on a clear path toward government approval. Pancreatic cancer is one of the most aggressive and difficult-to-treat cancers, and our mission remains focused on making a meaningful difference in this space for patients,” commented AIM Chief Executive Officer Thomas K. Equels.
Recent Highlights
- Resumed trading on the NYSE American;
- Closed public equity offering in July, raising $8.0 million in gross proceeds, which is expected to fund operations for approximately 12 months;
- Reported positive data in a mid-year update from the ongoing Phase 2 DURIPANC clinical study evaluating Ampligen in combination with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) in the treatment of metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX (See: NCT05927142 );
- Announced upcoming presentations at the International 5 th Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care;
- Ampligen oncology data was presented at scientific congresses including the Annual Meeting of the American Association of Immunologists and U.S.-Poland Science and Technology Symposium 2025.
For more information, please visit the Company’s website at aimimmuno.com .
Summary of Financial Highlights for Second Quarter 2025
- As of June 30, 2025, AIM reported cash, cash equivalents and marketable investments of $835,000.
- Research and development expenses for the three months ended June 30, 2025 were $1.2 million, compared to $1.1 million for the same period in 2024.
- General and administrative expenses were $1.5 million for the three months ended June 30, 2025, compared to $2.6 million for the same period 2024.
- The net loss from operations for the three months ended June 30, 2025 was $2.8 million, or $(3.68) per share, compared to $1.8 million, or $(3.00) per share, for the three months ended June 30, 2024.
Please refer to the full 10-Q for complete details.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen ® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X , LinkedIn , and Facebook .
Cautionary Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Publication of data, and pre-clinical and clinical success seen to date, does not guarantee that Ampligen will be approved for commercial treatment in any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
Investor Contact:JTC Team, LLCJenene Thomas908.824.0775AIM@jtcir.com
FAQ**
What specific findings from the mid-year report indicate that the combination of Ampligen and AstraZeneca’s Imfinzi may lead to improved patient outcomes in PANCREATIC CANCER, according to AIM ImmunoTech Inc. AIM's clinical data?
How does AIM ImmunoTech Inc. AIM plan to utilize the $8.0 million raised from its public equity offering to advance the development of Ampligen and support ongoing trials in pancreatic cancer?
Can you elaborate on the significance of the positive data reported from the DURIPANC clinical study and its implications for future approvals of Ampligen as a treatment option for pancreatic cancer by AIM ImmunoTech Inc. AIM?
Given the boost in cash reserves, what are the next critical milestones for AIM ImmunoTech Inc. AIM in the development pipeline for Ampligen, particularly regarding pancreatic cancer therapies, over the next 12 months?
**MWN-AI FAQ is based on asking OpenAI questions about AIM ImmunoTech Inc. (NYSE: AIM).
NASDAQ: AIM
AIM Trading
57.55% G/L:
$0.4038 Last:
448,184,778 Volume:
$0.2756 Open:
